It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Veracyte Inc (VCYT) USD0.001

Sell:$23.97 Buy:$42.00 Change: $1.36 (3.86%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Sell:$23.97
Buy:$42.00
Change: $1.36 (3.86%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Sell:$23.97
Buy:$42.00
Change: $1.36 (3.86%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Contact details

Address:
6000 Shoreline Ct Ste 300
SOUTH SAN FRANCISCO
94080-7606
United States
Telephone:
+1 (650) 2436300
Website:
https://www.veracyte.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VCYT
ISIN:
US92337F1075
Market cap:
$2.45 billion
Shares in issue:
67.25 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Bonnie Anderson
    Chairman of the Board, Chief Executive Officer
  • Marc Stapley
    Chief Executive Officer
  • Keith Kennedy
    Chief Financial Officer, Chief Operating Officer
  • James Erlinger
    Executive Vice President, General Counsel, Secretary
  • Beverly Alley
    Principal Accounting Officer, Vice President, Corporate Controller
  • Giulia Kennedy
    Chief Scientific Officer, Chief Medical Officer
  • Morten Frost
    General Manager - Pulmonology
  • John Hanna
    General Manager - Endocrinology, Breast Cancer and lymphoma

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.